Kaharu Sumino

Medicine & Life Sciences

1. Asthma 100%
2. Adrenal Cortex Hormones 27%
3. African Americans 21%
4. Metapneumovirus 20%
5. Methacholine Chloride 18%
6. Nebulizers and Vaporizers 17%
7. Randomized Controlled Trials 17%
8. Bronchial Thermoplasty 16%
9. Respiratory Syncytial Viruses 14%
10. Vitamin D 13%
11. Placebos 13%
12. Chronic Obstructive Pulmonary Disease 12%
13. Viruses 11%
14. DNA Vaccines 11%
15. Lung 10%
16. Medication Adherence 10%
17. Pandemics 9%
18. Respiratory Tract Infections 9%
19. Inflammation 9%
20. Hispanic Americans 9%
21. lebrikizumab 9%
22. Bocavirus 8%
23. Reminder Systems 8%
24. benralizumab 8%
25. HIV-1 8%
26. Infections 8%
27. saponin QA-21V1 8%
28. Orthomyxoviridae 7%
29. Virus Diseases 7%
30. Rhinovirus 7%
31. Vaccination 7%
32. Mucosal Immunity 7%
33. Comparative Effectiveness Research 7%
34. Safety 7%
35. Antiviral Agents 7%
36. Therapeutics 6%
37. Stakeholder Participation 6%
38. Esomeprazole 6%
39. Bronchodilator Agents 6%
40. Forced Expiratory Volume 6%
41. Pragmatic Clinical Trials 6%
42. Child 6%
43. Coronavirus 6%
44. Alendronate 6%
45. Treatment Failure 6%
46. Cholecalciferol 6%
47. H1N1 Subtype Influenza A Virus 5%
48. Isoflavones 5%
49. Optic Nerve Diseases 5%
50. Bronchiolitis 5%